OakChart

Dianthus Therapeutics Inc

DNTHHealthcare·Biotechnology·USA·Mid·NASD·Nov 12 • 3:59 PM ET

92.48+3.18 (3.56%)
2026-11-13 14:06 CET
Market cap
$5.21B
Revenue, TTM
2.72 USD m
Net income, TTM
-202.12 USD m
Free cash flow, TTM
-175.85 USD m
EPS diluted, TTM
-3.99
Price / earnings
-
Compare

Price

DNTH against its 20, 50 and 200-day averages
Terms2050200BeatMiss
Patternshover a marker to name it
RS 68Sales 0.45Price0.300.3960.0080.00100.00120.002.8M5.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DNTHclose 92.4820-day 82.2750-day 88.77200-day 86.7392.4852w high 117.8852-week range, not 6 months

21.5% under the 52-week high of 117.88 on 19 Aug 2026. 52-week low 34.29 on 14 Nov 2025. Last 15 sessions, 22.1% high to low

Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average

Setup. RS line 68
CANSLIM 3 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High
VCP 3 of 6 — fails: 52-Week High/Low: 0-10% below High; Average True Range: Under 2; RSI (14): Not Overbought (<60)
Minervini 3 of 4 — fails: 52-Week High/Low: 0-10% below High
Zanger 4 of 5 — fails: Relative Volume: Over 1.5
Leaders 4 of 5 — fails: 52-Week High/Low: 0-10% below High
Breakout 2 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%) — not on the tape: P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 4 of 4
Accumulation 3 of 4 — fails: Institutional Transactions: Over +10%
Relative Strength 3 of 3

Profile

DNTH
52-week range, 70% of the way up
34.29117.88

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

IndexRUT
Employees92
IPOJun 21, 2018
Beta1.45
ATR, 14d4.57
Rel volume0.00
Short float19.81%
Insider own16.86%
Inst own118.81%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap$5.21B
Enterprise Value4.37B
Income-202.12M
Sales2.72M
Book / share22.05
Cash / share14.88
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees92
IPOJun 21, 2018

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales1914.63
Price / book4.19
Price / cash6.22
Price / free cash flow-
Value / cash profit-
Value / sales1607.07
Quick Ratio30.02
Current Ratio30.02
Debt / equity0.00
Long-term debt / equity0.00
Options and shortYes / Yes

Earnings

Earnings / share-3.99
Earnings next year-4.38
Earnings next quarter-0.96
Earnings this year15.93%
Earnings next year-24.17%
Earnings growth, 5 years-7.48%
Past earnings growth49.46% 31.21%
Past sales growth-31.80% -
Earnings vs last year-14.33%
Sales vs last year-11.70%
Earnings vs last quarter16.39%
Sales vs last quarter205.56%
EarningsNov 04 AMC
Surprise14.24% 162.53%

Ownership

Insiders own16.86%
Insider trades-4.57%
Institutions own118.81%
Institution trades-2.47%
Return on assets-21.81%
Return on equity-22.61%
Return on capital-16.27%
Gross Margin85.69%
Operating margin-8683.89%
Profit Margin-7436.50%
20-day average12.41%
50-day average4.18%
200-day average6.63%

Technical

Shares out56.30M
Shares floating46.82M
Short / float19.81%
Short ratio11.05
Short interest9.28M
52-week high117.88 -21.5%
52-week low34.29 +169.7%
Volatility6.57% 5.59%
Average range4.57
Strength index64.70
Market sensitivity1.45
Relative volume0.00
Avg Volume839.66K
Volume0

Performance

Perf Week11.41%
Perf Month23.70%
Perf Quarter-20.25%
Perf Half Y8.37%
Perf YTD124.41%
Perf Year138.84%
Perf 3Y704.17%
Perf 5Y-21.79%
Perf 10Y-
Recommendation1.06
Target Price138.71
Prev Close92.48
Price92.48
Change %0.00%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 27, 2026InitiatedRoth CapitalBuy$113+22.2%
Sep 11, 2026InitiatedJP MorganOverweight$135+46.0%
Sep 04, 2026InitiatedCitigroupBuy$156+68.7%
Apr 09, 2026InitiatedWolfe ResearchOutperform$98+6.0%
Mar 10, 2026UpgradeRaymond JamesOutperform → Strong Buy$123+33.0%
Oct 14, 2025InitiatedTruistBuy$56-39.4%
Jul 02, 2025InitiatedWilliam BlairOutperform
Dec 20, 2024InitiatedTD CowenBuy
Oct 03, 2024InitiatedOppenheimerOutperform$48-48.1%
Jul 26, 2024InitiatedRobert W. BairdOutperform$58-37.3%

Peers

Mkt cap
TickerCompanyMkt cap
IMVTImmunovant Inc7.20B
ARGXArgen X SE ADR61.91B
ANNXAnnexon Inc758.32M
VRDNViridian Therapeutics Inc3.45B
KYTXKyverna Therapeutics Inc309.21M
RNACCartesian Therapeutics Inc193.85M
SNYSanofi ADR115.72B
CABACabaletta Bio Inc286.91M
AZNAstrazeneca plc286.19B
JNJJohnson & Johnson686.20B

Insider trading

latest 14 of 72
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Savitz RyanEVP, CFO & CBONov 09 '26Option Exercise19.38100,7131,952,149100,713Nov 12 05:32 PM
Savitz RyanEVP, CFO & CBONov 12 '26Option Exercise22.0517,724390,76717,724Nov 12 05:32 PM
Savitz RyanEVP, CFO & CBONov 11 '26Option Exercise21.903,04466,6583,044Nov 12 05:32 PM
Savitz RyanEVP, CFO & CBONov 10 '26Option Exercise21.922,56156,1312,561Nov 12 05:32 PM
Savitz RyanEVP, CFO & CBONov 09 '26Sale90.54100,7139,118,7340Nov 12 05:32 PM
Savitz RyanEVP, CFO & CBONov 12 '26Sale90.5617,7241,605,0850Nov 12 05:32 PM
Savitz RyanEVP, CFO & CBONov 11 '26Sale90.033,044274,0510Nov 12 05:32 PM
Savitz RyanEVP, CFO & CBONov 10 '26Sale90.142,561230,8490Nov 12 05:32 PM
RYAN SAVITZOfficerNov 09 '26Proposed Sale86.03124,04210,671,333Nov 09 04:36 PM
CARR EDWARDCHIEF ACCOUNTING OFFICERSep 17 '26Option Exercise17.8820,000357,60020,000Sep 18 04:36 PM
CARR EDWARDCHIEF ACCOUNTING OFFICERSep 17 '26Sale101.3820,0002,027,6460Sep 18 04:36 PM
EDWARD CARROfficerSep 17 '26Proposed Sale102.4920,0002,049,800Sep 17 04:28 PM
Randhawa SimratEVP, Head of R&DSep 01 '26Option Exercise20.6323,124477,04727,124Sep 03 04:30 PM
Randhawa SimratEVP, Head of R&DSep 01 '26Sale106.4123,1242,460,6904,000Sep 03 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
XBIState Street SPDR S&P Biotech ETFAUM: 10.59B
IWMiShares Russell 2000 Index FundAUM: 77.86B
VXFVanguard Extended Market Index ETFAUM: 30.79B
VBVanguard Morningstar Small-Cap ETFAUM: 80.23B
IWOiShares Russell 2000 Growth ETFAUM: 14.25B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.88B
SCHASchwab U.S. Small-Cap ETFAUM: 22.44B
VTWOVanguard Russell 2000 Index ETFAUM: 16.90B
TCAFT. Rowe Price Capital Appreciation Equity ETFAUM: 8.35B

News

latest 14 of 200
  • Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results (GlobeNewswire)
  • Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Dianthus Therapeutics to Participate in Five Investor Conferences During November (GlobeNewswire)
  • Dianthus Therapeutics Named to Fortune's 2026 Best Workplaces in BioPharma List Amid Company Expansion (InvestorsHub)
  • Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma (GlobeNewswire)
  • Top Bank Names 6 Stocks With Major Catalysts Ahead (GuruFocus.com)
  • Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting (GlobeNewswire)
  • UiPath downgraded, Shell upgraded: Wall Street's top analyst calls (The Fly)
  • Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Dianthus Therapeutics to Participate in Three Investor Conferences During September (GlobeNewswire)
  • Dick's Sporting Goods shares rise after Wells Fargo upgrade (InvestorsHub)
  • Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results (GlobeNewswire)
  • Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases (GlobeNewswire)

Quarterly earnings

2026Q3 EPS -0.810 beat -0.945, from -0.970 a year earlier. Sales 1.21 beat 0.46, from 0.40 a year earlier
EPS
0.0000-1.4302024Q4 EPS -0.810 against -0.85124Q42025Q1 EPS -0.820 against -0.85025Q12025Q2 EPS -0.880 against -0.87225Q22025Q3 EPS -0.970 against -0.86825Q32025Q4 EPS -1.430 against -1.00625Q42026Q1 EPS -0.850 against -1.07226Q12026Q2 EPS -0.900 against -0.84626Q22026Q3 EPS -0.810 against -0.94526Q3
Sales, USD millions
1.3302024Q4 sales 1.33 against 0.9624Q42025Q1 sales 1.16 against 0.8125Q12025Q2 sales 0.19 against 0.8625Q22025Q3 sales 0.40 against 0.5825Q32025Q4 sales 0.28 against 0.5525Q42026Q1 sales 0.46 against 0.4026Q12026Q2 sales 0.76 against 0.3026Q22026Q3 sales 1.21 against 0.4626Q3

The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.

PeriodReportedEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mSurpriseYear-ago quarterAnalystsNext session
2026Q3ended 2026-09-302026-11-04 16:30-0.810-0.945-0.8101.210.46EPS -14.2% · sales +162.5%vs 2025Q3, year-ago quarter · EPS -16.5% · sales +205.6%16 EPS · 15 salesOpen +0.07% vs SPY -0.17%. Close -3.26% vs SPY -4.41%
2026Q2ended 2026-06-302026-08-04 16:30-0.900-0.846-0.8960.760.30EPS +6.3% · sales +156.1%vs 2025Q2, year-ago quarter · EPS +2.3% · sales +294.3%12 EPS · 11 salesOpen -0.46% vs SPY +0.59%. Close +1.90% vs SPY -0.20%
2026Q1ended 2026-03-312026-05-05 16:30-0.850-1.072-0.8500.460.40EPS -20.7% · sales +14.7%vs 2025Q1, year-ago quarter · EPS +3.7% · sales -60.2%14 EPS · 13 salesOpen +1.74% vs SPY +0.61%. Close +0.20% vs SPY +1.39%
2025Q4ended 2025-12-312026-03-09 08:30-1.430-1.006-1.4330.280.55EPS +42.2% · sales -48.6%vs 2024Q4, year-ago quarter · EPS +76.5% · sales -78.6%12 EPS · 13 salesOpen +21.01% vs SPY -0.89%. Close +21.52% vs SPY +0.88%
2025Q3ended 2025-09-302025-11-05 16:30-0.970-0.868-0.9730.400.58EPS +11.8% · sales -31.2%vs 2024Q3, year-ago quarter · EPS +31.1% · sales -81.8%14 EPS · 10 salesOpen +0.36% vs SPY -0.16%. Close +8.00% vs SPY -1.07%
2025Q2ended 2025-06-302025-08-07 16:30-0.880-0.872-0.8830.190.86EPS +1.0% · sales -77.5%vs 2024Q2, year-ago quarter · EPS +72.5% · sales -89.6%12 EPS · 10 salesOpen -0.78% vs SPY +0.29%. Close -2.04% vs SPY +0.78%
2025Q1ended 2025-03-312025-05-12 16:30-0.820-0.850-0.8251.160.81EPS -3.5% · sales +44.1%vs 2024Q1, year-ago quarter · EPS +51.9% · sales +33.1%10Open -2.59% vs SPY +0.07%. Close -6.18% vs SPY +0.66%
2024Q4ended 2024-12-312025-03-11 16:30-0.810-0.851-0.8121.330.96EPS -4.8% · sales +38.7%vs 2023Q4, year-ago quarter · EPS +14.1% · sales +189.9%11 EPS · 9 salesOpen -6.54% vs SPY +1.12%. Close -6.33% vs SPY +0.53%
2024Q3ended 2024-09-302024-11-07 16:30-0.740-0.595-0.7352.170.74EPS +24.5% · sales +193.1%vs 2023Q3, year-ago quarter · EPS -80.4% · sales +135.1%9 EPS · 7 salesOpen +7.86% vs SPY +0.09%. Close -2.81% vs SPY +0.43%
2024Q2ended 2024-06-302024-08-08 16:30-0.510-0.545-0.5141.860.37EPS -6.5% · sales +405.0%vs 2023Q2, year-ago quarter · EPS -82.7% · sales +89.2%9 EPS · 7 salesOpen +0.97% vs SPY -0.16%. Close +2.84% vs SPY +0.44%
2024Q1ended 2024-03-312024-05-09 16:30-0.540-0.438-0.5360.870.46EPS +23.3% · sales +88.2%vs 2023Q1, year-ago quarter · EPS -92.8% · sales -5 EPS · 4 salesOpen +6.22% vs SPY +0.32%. Close -2.57% vs SPY +0.13%
2023Q4ended 2023-12-312024-03-21 16:30-0.710-0.940-0.7130.460.55EPS -24.5% · sales -16.7%vs 2022Q4, year-ago quarter · EPS -85.2% · sales -5 EPS · 4 salesOpen +6.05% vs SPY -0.02%. Close +14.32% vs SPY -0.19%
2023Q3ended 2023-09-302023-11-09 16:30-3.780-0.560-3.7790.920.25EPS +575.0% · sales +269.6%vs 2022Q3, year-ago quarter · EPS -12.5% · sales -2-
2023Q2ended 2023-06-302023-09-18 12:00-2.945-0.800-0.8660.980.00EPS +268.1% · sales -vs 2022Q2, year-ago quarter · EPS -36.5% · sales -1-
2023Q1ended 2023-03-312023-05-15 08:30-7.520-6.560-7.6960.000.00EPS +14.6% · sales -vs 2022Q1, year-ago quarter · EPS +20.5% · sales -1-
2022Q4ended 2022-12-312023-03-23 08:30-4.800-4.320-5.3240.000.00EPS +11.1% · sales -vs 2021Q4, year-ago quarter · EPS -9.1% · sales -3-

Annual earnings

2025FY EPS -4.200 missed -3.676, from -2.550 a year earlier. Sales 2.04 missed 2.20, from 6.24 a year earlier
EPS
0.0000-50.0802018FY EPS -50.080 against -43.64820182019FY EPS -33.120 against -32.29320192020FY EPS -27.360 against -26.94420202021FY EPS -20.640 against -19.53520212022FY EPS -18.240 against -18.78820222023FY EPS -8.450 against -5.53020232024FY EPS -2.550 against -2.56120242025FY EPS -4.200 against -3.6762025
Sales, USD millions
6.2402018FY sales 0.00 against 0.0020182019FY sales 0.00 against 0.0020192020FY sales 0.00 against 0.0020202021FY sales 0.00 against 0.0020212022FY sales 0.00 against 0.0020222023FY sales 2.83 against 2.4620232024FY sales 6.24 against 5.5420242025FY sales 2.04 against 2.202025

Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.

earnings feed, not the snapshot. Not the statement ratio.

PeriodEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mP/E, earnings feed
2030FYestimate-1.849--672.8850.02
2029FYestimate--3.973--155.33-
2028FYestimate--5.215--15.36-
2027FYestimate--4.385--2.45-
2026FYestimate--3.531--2.60-
2025FY-4.200-3.676-4.1882.042.20-
2024FY-2.550-2.561-2.5516.245.54-
2023FY-8.450-5.530-8.4522.832.46-
2022FY-18.240-18.788-32.5730.000.00-
2021FY-20.640-19.535-20.7130.000.00-
2020FY-27.360-26.944-27.2990.000.00-
2019FY-33.120-32.293-33.1840.000.00-
2018FY-50.080-43.648-50.1180.000.00-

Quarterly results

2026Q3 revenue 1.21, from 0.40 a year earlier. Operating margin -4,832%, from -10,073% a year earlier
Revenue, USD millions
1.3302024Q4 revenue 1.3324Q42025Q1 revenue 1.1625Q12025Q2 revenue 0.1925Q22025Q3 revenue 0.4025Q32025Q4 revenue 0.2825Q42026Q1 revenue 0.4626Q12026Q2 revenue 0.7626Q22026Q3 revenue 1.2126Q3
Operating margin
0.00-24,8362024Q4 operating margin -2,400%24Q42025Q1 operating margin -2,860%25Q12025Q2 operating margin -18,384%25Q22025Q3 operating margin -10,073%25Q32025Q4 operating margin -24,836%25Q42026Q1 operating margin -10,115%26Q12026Q2 operating margin -8,089%26Q22026Q3 operating margin -4,832%26Q3

From the quarterly statement. Not an estimate.

Estimate revisions

Latest snapshot of each period and type. 2026FY E -3.53 per share.
PeriodTypeScaleDateMeanvs prior date
2026FYEper share2026-11-13-3.53-0.2%
2026Q4Eper share2026-11-13-0.96+0.4%
2026FYRper share2026-11-13-3.50-0.7%
2026Q4Rper share2026-11-13-0.94-0.8%
2026FYSper share2026-11-132.60+3.2%
2026Q4Sper share2026-11-130.45+1.5%
2026Q3Rper share2026-10-26-0.94+0.3%
2026Q3Sper share2026-10-260.46+3.8%
2026Q3Eper share2026-10-23-0.94+0.1%
2026Q2Eper share2026-07-21-0.850.0%
2026Q2Rper share2026-07-21-0.740.0%
2026Q2Sper share2026-07-200.300.0%
2026Q1Eper share2026-04-21-1.060.0%
2026Q1Sper share2026-04-070.40-2.4%
2026Q1Rper share2026-03-18-0.90+3.7%
2025FYSper share2026-03-042.200.0%
2025FYEper share2026-02-27-3.680.0%
2025Q4Eper share2026-02-19-1.08+0.8%
2025FYRper share2026-02-18-4.02-2.4%
2025Q4Rper share2026-02-18-1.29-6.6%
2025Q4Sper share2026-02-180.58+6.3%
2025Q3Eper share2025-10-26-0.870.0%
2025Q3Rper share2025-10-22-0.860.0%
2025Q3Sper share2025-10-220.580.0%
2025Q2Eper share2025-07-27-0.870.0%
2025Q2Rper share2025-07-27-0.870.0%
2025Q2Sper share2025-07-270.860.0%
2025Q1Rper share2025-05-05-0.840.0%
2025Q1Eper share2025-05-02-0.85+0.1%
2025Q1Sper share2025-03-120.81-1.8%
2024FYEper share2025-02-20-2.56+1.3%
2024Q4Eper share2025-02-20-0.85+1.4%
2024FYSper share2025-01-255.540.0%
2024Q4Sper share2025-01-250.960.0%
2024FYRper share2025-01-22-2.620.0%
2024Q4Rper share2025-01-22-0.800.0%
2024Q3Eper share2024-10-23-0.590.0%
2024Q3Rper share2024-10-23-0.560.0%
2024Q3Sper share2024-10-230.740.0%
2024Q2Eper share2024-07-25-0.55+0.1%
2024Q2Sper share2024-07-250.37+17.6%
2024Q2Rper share2024-07-24-0.550.0%
2024Q1Eper share2024-04-17-0.44+0.2%
2024Q1Rper share2024-04-17-0.44+0.3%
2024Q1Sper share2024-03-220.46-2.2%
2023FYEper share2024-02-13-5.53-14.1%
2023FYSper share2024-02-132.46-13.7%
2023FYRper share2024-01-27-6.310.0%

Estimate history

Annual
Metric201720182019202020212022202320242025TTMMRQ
EPS per share-17.274-50.118-33.184-27.299-20.713-32.573-8.452-2.551-4.204-3.9925-
Sales USD millions0000063623-
Shares million shares222341153143-56
Quarterly
MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
EPS per share-0.735-0.812-0.825-0.883-0.973-1.433-0.85-0.896-0.813
Sales USD millions211000011
Shares million shares293132324343555556

Income statement, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Total Revenue2.722.04-67.3%6.24+120.5%2.83-55.9%6.420.000.000.000.00
Cost of Goods Sold Incl. D&A0.390.43+4.9%0.41+17.1%0.35+133.3%0.15-92.6%2.02+2.0%1.98+7.6%1.84+109.1%0.88
Gross Profit2.331.61-72.3%5.82+135.6%2.47-60.6%6.27-2.02-1.98-1.84-0.88
Selling, General and Administrative Excl. Other238.36179.54+66.7%107.69+112.6%50.65+40.8%35.98-50.5%72.67-5.3%76.72-5.4%81.13+37.3%59.09
Research and Development188.71145.64+75.2%83.11+153.1%32.84+11.8%29.38-34.3%44.75-8.0%48.64-15.2%57.37+38.8%41.34
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-236.03-177.93-101.86-48.17-29.70-74.69-78.70-82.97-59.96
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.00--
Net Income Before Taxes-202.12-162.34-84.97-43.55-28.48-71.14-74.94-76.77-57.52
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-202.12-162.34-84.97-43.55-28.48-71.14-74.94-76.77-57.52
Net Income From Continuing Operations-202.12-162.34-84.97-43.55-28.48-71.14-74.94-76.77-57.52
Net Income-202.12-162.34-84.97-43.55-28.48-71.14-74.94-76.77-57.60
EPS (Recurring) per share-3.52-4.20-2.55-8.45-32.57-20.71-27.30-33.18-50.12
EPS (Basic, Before Extraordinaries) per share-3.99-4.20-2.55-8.45-32.57-20.71-27.30-33.18-50.12
EPS (Diluted) per share-3.99-4.20-2.55-8.45-32.57-20.71-27.30-33.18-50.12
EBITDA-235.64-177.50-101.45-47.82-29.56-72.67-76.72-81.13-59.09
Non-Operating Income (Expense)33.9015.60-7.6%16.89+265.6%4.62+275.6%1.23-65.4%3.56-5.6%3.77-39.2%6.20+153.1%2.45
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense41.2022.79+76.8%12.89+344.5%2.90+90.8%1.52-85.3%10.31+3.7%9.94-0.6%10.00-6.5%10.70
Price To Sales Ratio ratio1,857.58781.65116.4818.970.86----
Gross Margin %85.6978.9893.3987.4497.71----
Operating Margin %-8,683.89-8,739.34-1,633.74-1,704.67-462.91----
Net Margin %-7,436.50-7,973.33-1,362.77-1,541.22-443.76----
Shares Outstanding million shares56.3043.22+38.9%31.12+110.0%14.82+1584.1%0.88-76.0%3.67+21.1%3.03+23.7%2.45+17.8%2.08
Market Capitalization5,207.805,207.80+707.1%645.21+318.7%154.10+544.2%23.92-90.8%260.48-31.5%380.50-36.1%595.19+213.5%189.84

Income statement, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Total Revenue1.21+202.5%0.76+300.0%0.46-60.3%0.28-78.9%0.40-81.6%0.19-89.8%1.16+33.3%1.33+189.1%
Cost of Goods Sold Incl. D&A0.11+10.0%0.11+10.0%0.08-38.5%0.10+25.0%0.10-16.7%0.10-9.1%0.13+18.2%0.08-20.0%
Gross Profit1.10+266.7%0.65+622.2%0.39-62.1%0.19-84.8%0.30-85.4%0.09-94.9%1.03+33.8%1.25+257.1%
Selling, General and Administrative Excl. Other59.57+46.8%62.14+77.4%46.92+37.2%69.73+110.3%40.59+27.0%35.02+46.2%34.21+83.8%33.16+149.1%
Research and Development45.60+40.4%48.69+85.5%34.53+27.9%59.90+126.8%32.49+27.2%26.25+45.3%27.00+106.4%26.41+200.8%
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-58.47-61.48-46.53-69.54-40.29-34.93-33.18-31.92
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-46.64-50.22-40.83-64.43-36.77-31.63-29.51-28.44
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-46.64-50.22-40.83-64.43-36.77-31.63-29.51-28.44
Net Income From Continuing Operations-46.64-50.22-40.83-64.43-36.77-31.63-29.51-28.44
Net Income-46.64-50.22-40.83-64.43-36.77-31.63-29.51-28.44
EPS (Recurring) per share-0.81-0.90-0.85-1.43-0.97-0.88-0.82-0.81
EPS (Basic, Before Extraordinaries) per share-0.81-0.90-0.85-1.43-0.97-0.88-0.82-0.81
EPS (Diluted) per share-0.81-0.90-0.85-1.43-0.97-0.88-0.82-0.81
EBITDA-58.36-61.38-46.46-69.44-40.19-34.83-33.04-31.84
Non-Operating Income (Expense)11.83+236.1%11.27+241.5%5.70+55.3%5.11+46.8%3.52-25.6%3.30-28.3%3.67-10.5%3.48+45.6%
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense12.72+119.7%11.90+108.4%10.60+99.2%5.98+52.6%5.79+50.8%5.71+84.2%5.32+160.8%3.92+437.0%
Price To Sales Ratio ratio1,857.582,868.553,017.15910.25483.17137.4999.52122.49
Gross Margin %90.9985.9483.5965.8575.0048.7088.5694.12
Operating Margin %-4,832.40-8,079.11-10,050.32-24,486.27-10,173.74-18,096.89-2,852.71-2,406.94
Net Margin %-3,854.79-6,598.55-8,819.44-22,687.32-9,284.09-16,388.08-2,537.49-2,144.80
Shares Outstanding million shares56.30+31.4%54.80+70.3%54.58+69.9%43.22+38.9%42.85+45.9%32.18+9.6%32.13+9.5%31.12+110.0%
Market Capitalization5,207.80+232.4%5,328.86+789.4%4,442.90+662.4%1,766.92+173.9%1,566.77+94.9%599.14-21.1%582.75-33.8%645.21+318.7%

Balance sheet, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/20182017FY12/31/2017
Cash & Short Term Investments404.30+46.9%275.24+58.4%173.72+130.1%75.49-57.3%176.93+18.9%148.84+2.1%145.73+2.2%142.57+176.5%51.57
Short Term Receivables0.10-90.1%1.01+110.4%0.48-91.5%5.640.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets5.04+8.2%4.66+43.4%3.25+257.1%0.91-75.9%3.77+40.1%2.69-34.5%4.11+49.5%2.75+192.6%0.94
Total Current Assets409.44+45.8%280.90+58.3%177.45+116.3%82.03-54.6%180.69+19.2%151.53+1.1%149.84+3.1%145.32+176.8%52.50
Net Property, Plant & Equipment1.63-6.9%1.75+118.8%0.80-16.7%0.96-87.1%7.46-10.2%8.31-16.0%9.89+222.1%3.07+76.4%1.74
Total Investments and Advances110.14+34.8%81.73+116657.1%0.07+16.7%0.06-96.6%1.780.0%1.780.0%1.78-80.0%8.92+3954.5%0.22
Intangible Assets---0.000.000.000.000.00-
Deferred Tax Assets0.48+108.7%0.23-------
Other Assets9.72+0.9%9.63+783.5%1.09+1716.7%0.060.000.000.000.000.00
Total Assets531.40+42.0%374.24+108.6%179.41+115.9%83.11-56.2%189.93+17.5%161.62+0.1%161.51+2.7%157.31+188.9%54.46
Short Term Debt Incl. Current Port. of LT Debt0.37+15.6%0.32-23.8%0.42+20.0%0.350.000.000.000.000.00
Accounts Payable9.72+112.2%4.58+75.5%2.61+123.1%1.17-61.5%3.04-19.1%3.76+33.8%2.81-19.5%3.49+1952.9%0.17
Other Current Liabilities20.64+52.3%13.55+105.3%6.60-1.6%6.71-14.2%7.82+2.0%7.67-32.1%11.30+63.1%6.93+74.1%3.98
Total Current Liabilities30.73+66.6%18.45+91.6%9.63+17.2%8.22-24.3%10.86-5.0%11.43-19.1%14.12+35.5%10.42+151.7%4.14
Long Term Debt1.02-12.8%1.17+588.2%0.17-61.4%0.440.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.48+108.7%0.23-------
Other Liabilities5.77+202.1%1.91+158.1%0.74-6.3%0.79-87.7%6.40+1.9%6.28+1.1%6.21+396.8%1.250.00
Total Liabilities38.00+74.6%21.76+106.5%10.54+11.5%9.45-45.2%17.26-2.5%17.71-12.8%20.32+74.3%11.66+181.6%4.14
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.00-100.0%118.020.000.000.000.00-100.0%92.44
Common Equity493.40+40.0%352.48+108.7%168.87-44.37-125.7%172.67+20.0%143.91+1.9%141.19-3.1%145.65-42.12
Total Shareholders Equity493.40+40.0%352.48+108.7%168.87+129.3%73.66-57.3%172.67+20.0%143.91+1.9%141.19-3.1%145.65+189.4%50.32
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity493.40+40.0%352.48+108.7%168.87+129.3%73.66-57.3%172.67+20.0%143.91+1.9%141.19-3.1%145.65+189.4%50.32
Total Liabilities & Stockholders Equity531.40+42.0%374.24+108.6%179.41+115.9%83.11-56.2%189.93+17.5%161.62+0.1%161.51+2.7%157.31+188.9%54.46
Book Value Per Share per share11.42+0.8%11.33-0.6%11.40-50.69-207.9%46.99-0.9%47.44-17.6%57.54-17.8%69.97-20.49
Tangible Book Value Per Share per share11.42+0.8%11.33-0.6%11.40-50.69-207.9%46.99-0.9%47.44-17.6%57.54-17.8%69.97-20.49
Full-Time Employees people92+17.9%78+47.2%53+12.8%47-37.3%75+8.7%69-4.2%72--
Price to Book Ratio ratio4.191.890.860.191.512.644.221.301.18
Return on Assets %-35.85-30.69-26.72-20.86-40.47-46.38-48.16-54.32-107.87
Return on Equity %-38.38-32.60-31.70-23.12-44.94-52.57-53.53-58.70-119.57
Return on Invested Capital %-32.83-24.03-25.77-38.43-41.20-52.07-54.37-39.49-70.53
Quick Ratio ratio13.3215.2218.429.9716.6313.2610.6213.9512.68
Current Ratio ratio13.3215.2218.429.9716.6313.2610.6213.9512.68

Cash flow, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Net Income-202.12-162.34-84.97-43.55-28.48-71.14-74.94-76.77-57.52
Depreciation0.390.43+4.9%0.41+17.1%0.35+133.3%0.15-92.6%2.02+2.0%1.98+7.6%1.84+109.1%0.88
Other Funds (Non Cash)32.5116.12+139.5%6.73+354.7%1.48+62.6%0.91-91.8%11.11+9.8%10.12+12.6%8.99-16.5%10.77
Funds from Operations-169.23-145.79-77.83-41.72-27.42-58.01-62.84-65.93-45.87
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-5.9316.73-0.35-107.2%4.86-1.65-1.53-1.19-113.5%8.83+121.9%3.98
Cash from Operating Activities-175.15-129.06-78.18-36.86-29.07-59.53-64.02-57.10-41.89
Capital Expenditures-0.70-0.21-0.10-0.11-0.14-1.26-0.40-3.06-7.67
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-100.0%0.01
Purchase or Sale of Investments-686.46-122.62-286.71-1508.2%20.36-59.68-233.5%44.69-10.23-322.9%4.59-84.04
Purchase of Investments-1,182.19-435.01-413.71-57.42-61.68-45.31-95.73-144.37-84.04
Sale Or Maturity of Investments495.73312.39+146.0%127.00+63.3%77.78+3789.0%2.00-97.8%90.00+5.3%85.50-42.6%148.960.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-687.16-122.83-286.81-1516.3%20.25-59.82-237.7%43.43-10.63-794.8%1.53-91.70
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock862.15280.12+9.6%255.62+2556100.0%0.01-100.0%96.68+7.9%89.60+32.3%67.74+8.7%62.30-56.2%142.15
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock862.15280.12+9.6%255.62+2556100.0%0.01-100.0%96.68+7.9%89.60+32.3%67.74+8.7%62.30-56.2%142.15
Proceedsfrom Stock Options833.05272.22+7.0%254.530.00-100.0%96.68+12.1%86.24+33.4%64.67+7.3%60.28-57.6%142.12
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-100.0%133.570.000.000.000.000.00
Other Financing Activities Uses0.000.000.00-8.170.000.000.000.000.00
Cash from Financing Activities862.15280.12+9.6%255.62+91.4%133.57+38.2%96.68+7.9%89.60+32.3%67.74+8.7%62.30-56.2%142.15
Net Change in Cash-0.1728.23-109.37-193.5%116.97+1401.5%7.79-89.4%73.50-6.92-202.8%6.73-21.4%8.56
Free Cash Flow-175.85-129.27-78.28-36.97-29.21-60.80-64.42-60.16-49.56
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Cash & Short Term Investments837.78+108.1%886.81+244.5%1,111.26+322.2%404.30+46.9%402.61+43.2%257.39-28.6%263.23-30.2%275.24+58.4%
Short Term Receivables0.63-87.4%0.31+121.4%1.31+0.8%0.10-90.1%5.00+86.6%0.14-91.7%1.30+47.7%1.01+110.4%
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets17.62+183.7%10.42+71.4%7.34+13.4%5.04+8.2%6.21+68.8%6.08+83.7%6.47+115.0%4.66+43.4%
Total Current Assets856.04+106.9%897.54+240.5%1,119.91+313.3%409.44+45.8%413.82+43.9%263.61-27.9%271.00-28.9%280.90+58.3%
Net Property, Plant & Equipment1.90+27.5%1.64+3.8%1.57-4.3%1.63-6.9%1.49+175.9%1.58+150.8%1.64+127.8%1.75+118.8%
Total Investments and Advances406.04+165.3%303.80+484.9%114.04+66.4%110.14+34.8%153.04+148.0%51.94+74100.0%68.54+97814.3%81.73+116657.1%
Deferred Tax Assets---0.48+108.7%---0.23
Other Assets12.27+35.0%10.29+15.0%11.37+53.6%9.72+0.9%9.09+101.6%8.95+246.9%7.40+900.0%9.63+783.5%
Total Assets1,276.25+121.0%1,213.27+272.1%1,246.88+257.7%531.40+42.0%577.45+63.0%326.08-11.6%348.58-8.9%374.24+108.6%
Short Term Debt Incl. Current Port. of LT Debt0.35+59.1%0.37+76.2%0.40+73.9%0.37+15.6%0.22-29.0%0.21-44.7%0.23-42.5%0.32-23.8%
Accounts Payable5.50-18.0%6.39+18.3%5.27-36.3%9.72+112.2%6.71-11.4%5.40+46.3%8.27+216.9%4.58+75.5%
Other Current Liabilities22.67+33.9%27.62+90.7%32.61+285.5%20.64+52.3%16.93+116.2%14.48+143.0%8.46+42.2%13.55+105.3%
Total Current Liabilities28.52+19.5%34.39+71.2%38.28+125.8%30.73+66.6%23.86+51.9%20.09+100.3%16.95+89.2%18.45+91.6%
Long Term Debt0.86-19.6%0.91-18.8%0.96-17.9%1.02-12.8%1.071.12+3633.3%1.17+1070.0%1.17+588.2%
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities---0.48+108.7%---0.23
Other Liabilities5.45-10.2%5.94+233.7%6.32+241.6%5.77+202.1%6.07+848.4%1.78+161.8%1.85+156.9%1.91+158.1%
Total Liabilities34.82+12.4%41.25+79.3%45.57+128.2%38.00+74.6%30.99+89.5%23.00+114.2%19.97+104.2%21.76+106.5%
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity1,241.43+127.2%1,172.03+286.7%1,201.31+265.6%493.40+40.0%546.45+61.7%303.08-15.4%328.61-11.8%352.48+108.7%
Total Shareholders Equity1,241.43+127.2%1,172.03+286.7%1,201.31+265.6%493.40+40.0%546.45+61.7%303.08-15.4%328.61-11.8%352.48+108.7%
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity1,241.43+127.2%1,172.03+286.7%1,201.31+265.6%493.40+40.0%546.45+61.7%303.08-15.4%328.61-11.8%352.48+108.7%
Total Liabilities & Stockholders Equity1,276.25+121.0%1,213.27+272.1%1,246.88+257.7%531.40+42.0%577.45+63.0%326.08-11.6%348.58-8.9%374.24+108.6%
Book Value Per Share per share22.05+72.9%21.39+127.1%22.01+115.2%11.42+0.8%12.75+10.8%9.42-22.8%10.23-19.4%11.33-0.6%
Tangible Book Value Per Share per share22.05+72.9%21.39+127.1%22.01+115.2%11.42+0.8%12.75+10.8%9.42-22.8%10.23-19.4%11.33-0.6%
Full-Time Employees people---92+17.9%---78+47.2%
Price to Book Ratio ratio4.194.437.353.234.181.821.601.89
Return on Assets %-21.81-24.98-21.77-35.85-27.12-33.02-27.56-30.69
Return on Equity %-22.61-26.07-22.70-38.38-28.57-34.71-28.73-32.60
Return on Invested Capital %-3.75-4.28-3.40-13.03-6.71-10.40-8.95-8.04
Quick Ratio ratio30.0226.1029.2513.3217.3513.1215.9915.22
Current Ratio ratio30.0226.1029.2513.3217.3513.1215.9915.22

Cash flow, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Net Income-46.64-50.22-40.83-64.43-36.77-31.63-29.51-28.44
Depreciation0.11+10.0%0.11+10.0%0.08-38.5%0.10+25.0%0.10-16.7%0.10-9.1%0.13+18.2%0.08-20.0%
Other Funds (Non Cash)11.81+262.3%6.14+33.8%9.69+184.2%4.87+263.4%3.26+173.9%4.59+71.3%3.41+124.3%1.34+570.0%
Funds from Operations-34.72-43.97-31.07-59.47-33.41-26.94-25.97-27.02
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-15.61-647.7%-5.01-264.3%2.2212.482.85+9.6%3.05+951.7%-1.66-0.42
Cash from Operating Activities-50.33-48.98-28.86-46.98-30.55-23.89-27.63-27.44
Capital Expenditures-0.37-0.18-0.01-0.14-0.01-0.05-0.02-0.03
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-111.51-478.34-1905.7%-133.96-1003.9%37.34-201.2726.49+2126.1%14.82-23.08
Purchase of Investments-323.10-565.76-238.59-54.73-279.84-33.11-67.32-108.08
Sale Or Maturity of Investments211.60+169.3%87.43+46.7%104.62+27.4%92.08+8.3%78.57+313.5%59.60+645.0%82.14+447.6%85.00+372.2%
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-111.87-478.52-1909.1%-133.97-1005.8%37.20-201.2826.45+2160.7%14.79-23.11
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock107.47-60.9%10.38+1721.1%739.41+462031.3%4.88-87.7%274.51+91403.3%0.57-99.7%0.16-40.7%39.68
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock107.47-60.9%10.38+1721.1%739.41+462031.3%4.88-87.7%274.51+91403.3%0.57-99.7%0.16-40.7%39.68
Proceedsfrom Stock Options98.31-63.9%-0.20735.13+565384.6%-0.19-100.5%272.28-0.00-100.0%0.1339.20
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.00-100.0%0.00
Other Financing Activities Uses0.000.000.000.000.000.00-100.0%0.000.00
Cash from Financing Activities107.47-60.9%10.38+1721.1%739.41+462031.3%4.88-87.7%274.51+91403.3%0.570.16-99.9%39.68
Net Change in Cash-54.73-228.2%-517.12-16674.4%576.58-4.9042.683.12-12.68-106.4%-10.88
Free Cash Flow-50.70-49.16-28.87-47.12-30.56-23.94-27.65-27.48

Revenue breakdown

USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.

Product
Name20242025vs 20242025 share
Total Pharmaceutical Preparations revenue6.242.04-67.3%100.0%
Total6.242.04-67.3%100.0%
Region
Name20242025vs 20242025 share
United States6.242.04-67.3%100.0%
Total6.242.04-67.3%100.0%

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3019.81%9.3M46.8M817.10K
2026-10-1519.32%9.0M46.5M809.00K
2026-09-3019.65%9.1M46.5M832.97K
2026-09-1518.98%8.8M46.5M932.88K
2026-08-3116.69%8.4M50.5M1.04M
2026-08-1418.10%8.4M46.5M1.05M
2026-07-3117.85%8.4M46.9M1.01M
2026-07-1520.10%9.2M45.9M933.25K
2026-06-3020.78%9.5M45.9M910.98K
2026-06-1515.22%7.0M45.9M822.95K
2026-05-2913.52%6.7M49.5M931.50K
2026-05-1513.00%6.4M49.5M932.56K
2026-04-3012.93%6.6M50.7M967.74K
2026-04-1514.50%6.6M45.3M1.07M
2026-03-3120.56%9.1M44.1M1.08M
2026-03-1324.81%9.2M37.1M978.27K
2026-02-2721.91%7.9M36.0M731.36K
2026-02-1322.49%8.1M36.0M797.54K
2026-01-3024.01%8.3M34.6M778.61K
2026-01-1523.80%7.4M31.0M689.84K

Option chain

Expiry 2026-11-20 · underlying 92.48, quoted 12 Nov 15:59 ET · ATM 90.00

Option quotes 10 Nov 12:50 ET. A date on a row is older than the last session (12 Nov). 54 rows.

Implied move 8.70% into expiry (call 5.350 + put 2.700 = 8.050 on 92.48)

Put/call open interest 0.04 (209 puts / 5,964 calls) · Put/call volume — no calls

IV change is points against the prior close.

TypeStrikeMoneyBidAskLastChgIVOpen intVolumeLast sizeDeltaThetaVega
call 1 Jan40.00ITM50.5055.000.000.00489.2% -51.40000.927-0.6500.019
put 1 JanOTM0.004.900.000.00540.5% 0.0000-0.073-0.6450.019
call 1 Jan45.00ITM45.5050.000.000.00430.8% -46.50000.916-0.6380.021
put 16 AprOTM0.004.901.800.00477.2% 0.0100-0.084-0.6330.021
call 23 Sep50.00ITM40.5045.0043.630.00378.9% -42.22000.904-0.6230.023
put 15 AprOTM0.004.902.650.00417.2% 0.0100-0.122-0.6590.026
call 1 Jan55.00ITM35.5040.000.000.00331.9% -38.50000.891-0.6040.025
put 1 JanOTM0.004.900.000.00359.9% 0.0000-0.114-0.5820.026
call 20 Oct60.00ITM30.5035.0017.800.00288.8% -35.113000.875-0.5810.028
put 1 JanOTM0.004.900.000.00323.9% 0.0000-0.125-0.5750.028
call 16 Apr65.00ITM25.5029.8035.890.00241.4% -39.31000.857-0.5540.031
put 28 SepOTM0.004.902.200.00265.1% 0.0100-0.191-0.5610.034
call 20 Oct70.00ITM20.5024.808.750.00204.4% -35.64000.834-0.5230.034
put 22 OctOTM0.004.902.440.00220.2% 0.01000-0.225-0.5130.038
call 20 Oct75.00ITM15.5019.807.550.00168.9% -32.2102000.805-0.4850.037
put 10 NovOTM0.004.900.500.00201.1% 0.01300-0.195-0.4760.037
call 2 Nov80.00ITM10.5014.906.250.00137.0% -26.25,380000.767-0.4380.041
put 9 NovOTM0.003.901.500.00163.3% 0.011200-0.233-0.4290.041
call 2 Nov85.00ITM6.0010.803.750.00113.3% -11.020000.712-0.3730.046
put 10 NovOTM0.003.402.500.00125.4% +1.93000-0.287-0.3600.046
call 9 Nov90.00ATM3.707.002.480.0067.1% -30.2126000.606-0.3300.052
put 28 SepATM0.504.9011.000.00114.5% +13.63100-0.396-0.3310.052
call 4 Nov95.00OTM0.004.900.690.00110.4% +2.3105000.466-0.3760.054
put 21 AugITM3.007.009.000.00104.2% -4.0100-0.534-0.3650.054
call 4 Nov100OTM0.004.901.150.00144.0% +3.54000.393-0.4710.052
put 30 OctITM6.1010.5018.250.00108.2% -32.3600-0.607-0.4600.052
call 4 Nov105OTM0.004.900.800.00172.2% 0.06000.354-0.5570.050
put 22 SepITM11.0015.0015.000.00123.9% -48.4300-0.646-0.5460.050
call 9 Nov110OTM0.004.900.930.00247.0% 0.011000.302-0.6740.044
put 1 JanITM15.2020.000.000.00146.6% -50.5000-0.675-0.6040.049
call 4 Nov115OTM0.004.900.450.00267.3% 0.012000.287-0.7130.043
put 1 JanITM20.8025.000.000.00167.0% -52.4000-0.697-0.6530.047
call 22 Oct120OTM0.004.900.250.00286.2% 0.034000.275-0.7470.042
put 1 JanITM25.2030.000.000.00185.7% -54.1000-0.713-0.6950.046
call 27 Oct125OTM0.004.900.300.00281.8% 0.01000.266-0.7530.043
put 1 JanITM30.1035.000.000.00202.9% -55.7000-0.727-0.7320.045
call 13 Jul130OTM0.004.908.200.00292.4% 0.01000.258-0.7860.043
put 1 JanITM35.2040.000.000.00219.0% -57.0000-0.738-0.7650.044
call 21 Sep135OTM0.004.902.350.00335.4% 0.07000.249-0.8320.040
put 1 JanITM40.1045.000.000.00234.0% -58.3000-0.748-0.7940.043
call 5 Nov140OTM0.004.900.100.00307.6% 0.096000.244-0.8370.043
put 18 AugITM45.2050.0032.800.00248.2% -59.4000-0.756-0.8210.043
call 27 Oct145OTM0.004.900.300.00363.5% 0.01000.237-0.8770.039
put 1 JanITM50.3055.000.000.00261.6% -60.4000-0.763-0.8460.042
call 1 Jan150OTM0.004.900.000.00349.2% 0.00000.230-0.8860.040
put 1 JanITM55.2060.000.000.00274.3% -61.4000-0.769-0.8690.041
call 14 Sep155OTM0.004.902.250.00344.5% 0.02000.208-0.8310.038
put 1 JanITM60.1065.000.000.00286.4% -62.3000-0.775-0.8900.041
call 3 Sep160OTM0.004.902.200.00346.2% 0.02000.195-0.8050.037
put 1 JanITM65.1070.000.000.00297.9% -63.1000-0.779-0.9100.040
call 3 Sep165OTM0.004.901.800.00412.0% 0.034000.219-0.9510.037
put 1 JanITM71.0075.000.000.00309.0% -63.8000-0.784-0.9280.040
call 1 Jan170OTM0.004.900.000.00400.0% 0.00000.212-0.9600.038
put 1 JanITM75.2080.000.000.00319.5% -64.5000-0.788-0.9460.039

Latest SEC filings

30 of 660
AllAll annual, quarterly, and current reportsInsider equity awards, transactions, and ownership (Section 16 Reports)Beneficial ownership reportsExempt offeringsRegistration statements and prospectusesFiling review correspondenceSEC orders and noticesProxy materialsTender offers and going private transactionsTrust indenture filings

10-Q filed 2026-11-04, period ended 2026-09-30. 10-K filed 2026-03-09, period ended 2025-12-31. DNTH on EDGAR

page 1 of 22Next →
FiledFormDescriptionPeriodDocument
2026-11-124Insider equity awards, transactions, and ownership (Section 16 Reports)2026-11-09 · transaction0001992324-26-000010 index
2026-11-09144no categoryno report period0001950047-26-010869 index
2026-11-0410-QAll annual, quarterly, and current reports2026-09-300001690585-26-000040 index
2026-11-048-KAll annual, quarterly, and current reports2026-11-040001690585-26-000039 index
2026-10-30SCHEDULE 13GBeneficial ownership reportsno report period0002100119-26-001565 index
2026-09-184Insider equity awards, transactions, and ownership (Section 16 Reports)2026-09-17 · transaction0001273351-26-000006 index
2026-09-18S-3ASRRegistration statements and prospectusesno report period0001193125-26-395502 index
2026-09-17144no categoryno report period0001950047-26-009619 index
2026-09-034Insider equity awards, transactions, and ownership (Section 16 Reports)2026-09-01 · transaction0001992260-26-000009 index
2026-09-01144no categoryno report period0001950047-26-008950 index
2026-08-194Insider equity awards, transactions, and ownership (Section 16 Reports)2026-08-19 · transaction0001688199-26-000006 index
2026-08-144Insider equity awards, transactions, and ownership (Section 16 Reports)2026-08-13 · transaction0001778623-26-000009 index
2026-08-14SCHEDULE 13G/ABeneficial ownership reportsno report period0000919574-26-005203 index
2026-08-13SCHEDULE 13GBeneficial ownership reportsno report period0000902219-26-000243 index
2026-08-114Insider equity awards, transactions, and ownership (Section 16 Reports)2026-08-10 · transaction0001779934-26-000004 index
2026-08-114Insider equity awards, transactions, and ownership (Section 16 Reports)2026-08-07 · transaction0001778623-26-000007 index
2026-08-114Insider equity awards, transactions, and ownership (Section 16 Reports)2026-08-10 · transaction0001688199-26-000004 index
2026-08-10144no categoryno report period0001974158-26-000096 index
2026-08-10144no categoryno report period0001950047-26-007911 index
2026-08-10144no categoryno report period0001950047-26-007887 index
2026-08-07144no categoryno report period0001950047-26-007814 index
2026-08-07144no categoryno report period0001950047-26-007811 index
2026-08-07144no categoryno report period0001950047-26-007793 index
2026-08-07SCHEDULE 13G/ABeneficial ownership reportsno report period0001897612-26-000577 index
2026-08-07SCHEDULE 13GBeneficial ownership reportsno report period0001897612-26-000576 index
2026-08-074Insider equity awards, transactions, and ownership (Section 16 Reports)2026-08-07 · transaction0001669866-26-000010 index
2026-08-0410-QAll annual, quarterly, and current reports2026-06-300001690585-26-000034 index
2026-08-048-KAll annual, quarterly, and current reports2026-08-040001690585-26-000033 index
2026-07-28SCHEDULE 13G/ABeneficial ownership reportsno report period0002012383-26-002551 index
2026-07-134Insider equity awards, transactions, and ownership (Section 16 Reports)2026-07-09 · transaction0001992324-26-000008 index

Insider activity by month

MonthBoughtBuysSoldSells
2026-110011.23M4
2026-100000
2026-09004.49M2
2026-080021.63M6
2026-07003.16M1
2026-06004.83M2
2026-050051.20K1
2026-0400738.84K1
2026-030028.03M6
2026-020000
2026-010000
2025-1200903.60K1
2025-11007.38M2

Institutional holders

Manager% owned
FMR LLC15.29%
BlackRock, Inc.7.54%
T. Rowe Price Investment Management, Inc.7.11%
WELLINGTON MANAGEMENT GROUP LLP5.91%
Fairmount Funds Management LLC4.64%
PRICE T ROWE ASSOCIATES INC /MD/4.60%
STATE STREET CORP4.53%
VANGUARD CAPITAL MANAGEMENT LLC3.95%
Avidity Partners Management LP3.85%
Octagon Capital Advisors LP3.37%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
Fidelity Growth Company Fund2.85%
VANGUARD HEALTH CARE FUND2.75%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.38%
iShares Russell 2000 ETF2.22%
T. Rowe Price Small-Cap Stock Fund, Inc.2.11%
Fidelity Advisor Biotechnology Fund1.34%
T. Rowe Price New Horizons Fund, Inc.1.23%
T. Rowe Price Institutional Small-Cap Stock Fund1.14%
Fidelity Small Cap Index Fund0.95%

OakChart. DNTH. Cached 15 minutes. Terms